BACKGROUND AND AIM: Red blood cell distribution width (RDW) elevation occurs in various inflammatory/infectious conditions. RDW levels during monitoring have not been investigated prospectively in community-acquired pneumonia (CAP). In CAP, the relationship between antibiotherapy response and RDW levels is unclear.
Introduction
P neumonia is a significant cause of mortality and morbidity. While there has been a decrease in morbidity and mortality in many other infectious diseases due to widespread vaccination programs and advanced antibiotic procedures, the same success has not been achieved in community-acquired pneumonia (CAP).
Pneumonia is one of the main causes of infection-related deaths in the USA and Great Britain and stands in the sixth place in terms of general causes of death. Mortality levels have been reported to be 1%-5% for outpatients, 12% for hospitalized patients, and approximately 40% for those treated in intensive care units (ICUs). [1] [2] [3] [4] Several markers are widely used for diagnosis, treatment, and follow-up of CAP such as C-reactive protein (CRP) and procalcitonin, and also there are some used for assessment of the severity of the disease such as CURB-65 and the pneumonia severity index (PSI). The PSI and CURB-65 are age dependent, and an elevated score in a young adult is a cause for concern. Red blood cell distribution width (RDW) is a technique involving the calculation of size variation among circulating red blood cells. RDW elevation occurs in various inflammatory conditions. High RDW levels have been shown to be associated with poor prognosis in CAP in previous studies. [5, 6] However, those studies were retrospective, and the course of RDW levels during monitoring was not investigated. The relationship between antibiotherapy response and RDW levels is therefore unclear.
The purpose of this prospective study was to investigate the prognostic role of RDW in CAP at the time of presentation and its current role in assessing the response to treatment.
Materials and Methods
Permission for this prospective, observational, descriptive study was granted by the ethics committee of Recep Tayyip Erdogan University. It was designed and conducted in accordance with the Declaration of Helsinki, between January 15, 2013, and September 31, 2013, in our pulmonology clinic. All subjects gave informed consent. We recruited 65 consecutive inpatients. Total complete blood cell (CBC) count, blood biochemistry analysis, and arterial blood gas tests were performed. Pulmonary X-rays were taken. Diagnosis of CAP was based on the modern Infectious Diseases Society of America and American Thoracic Society guidelines. [7] At least one clinical finding (yellow, dense phlegm, cough temperature >37.8°C) or at least two minor criteria (tachypnea, dyspnea, impaired orientation, pleural pain, pulmonary consolidation or leukocyte count >12,000 cells/µL) in addition to infiltrative changes at pulmonary X-ray were determined as diagnostic criteria for CAP. Severity of pneumonia was calculated on the basis of PSI and CURB-65 values. The patients who hospitalized due to low general health status but have low CURB-65 and PSI scores were also included in the study. Patients were started on empiric treatment. Venous blood samples were collected, and full blood count, CRP, and erythrocyte sedimentation rate (ESR) tests were performed on the 1 st and 7 th days. Patients' demographic characteristics, accompanying diseases, pneumonia symptoms, and findings and laboratory results were recorded.
Exclusion criteria
Patients who were referred from another hospital within the previous 15 days, patients who required ICU hospitalization, patients who were receiving antibiotherapy at presentation, patients with acute pulmonary embolism or severe immune deficiency and severe neutropenia, those receiving >10 mg prednisolone therapy for more than 1 month, patients with HIV positivity or active pulmonary tuberculosis, and patients aged under 18 were excluded. [5] Laboratory analysis CBC was calculated on admission with an automated hematology analyzer (Cell-Dyn Ruby 100 Test/h, 2012, Abbott). RDW values were obtained as part of the CBC results. The normal reference value for RDW in our hospital laboratory ranges was between 11.6% and 14.8%.
Arterial blood gas was taken from the radial artery with the patient in a seated posture after resting for 15 min, and analysis was performed immediately using a blood gas device (RAPIDLYLab 248/348 system, Siemens AG Healthcare, Germany).
Serum CRP levels were measured using the immunoturbidimetric method (Roche Diagnostics, GmbH, Mannheim, Germany). A normal reference value of 0.5 mg/dl was employed.
Statistical analysis
Compatibility of the study data with normal distribution was investigated using the Kolmogorov-Smirnov test. Results were expressed as mean (standard deviation) or median (quartiles). Student's t-test, the Mann-Whitney test, Fisher's exact test, one-way analysis of variance, and the Kruskal-Wallis test was employed, as appropriate, for intergroup comparisons. The paired sample t-test or Wilcoxon's test were determined to compare differences between baseline and subsequent data, depending on normal distribution. The Spearman or Pearson tests were used to assess correlation between variables. Receiver-operating characteristic (ROC) analysis was used to assess optimal cutoff values of RDW for 30-day mortality. Multivariate logistic regression analysis of predictor factors was performed based on a stepwise descending model with significance set at P < 0.01 for univariate analysis. P < 0.05 was considered statistically significant. Data were collected on SPSS for Mac 20.0 package program (SPSS Inc, Chicago, IL, USA) statistical software.
30-day mortality with 78% sensitivity and 70% specificity. Univariate screening (as described in the Materials and Methods section) was used to assess all potential factors for 
Results
Sixty-five patients with CAP were enrolled in the study. Sixty-five percent (42 patients) were male and the mean age was 69 years. Baseline data for the study population are shown in Table 1 Accompanying comorbidities were chronic obstructive pulmonary disease at 30.8%, congestive heart failure at 15.4%, diabetes mellitus at 9.2%, cerebrovascular disease at 7.7%, and cancer at 1.5%. All accompanying comorbidities were under control. The 30-day mortality rate was 13.8% (9 patients). Mean length of hospitalization was 8 days. [7] [8] [9] [10] Five (8%) patients required admission to the ICU.
The total mean RDW level was 16.2% ± 1.9%. The level was 17.7% ± 2.1% in nine nonsurviving patients and 15.9% ± 1.8% in surviving patients (P = 0.01). RDW level was lowest in the PSI-I group and highest in the PSI-V group. However, no statistically significant difference was determined among the groups. RDW levels were lowest in patients with a CURB-65 score of 0 and highest in CURB-IV. No significant difference was again determined among the groups [ Table 2 ].
RDW, leukocyte, and CRP levels were investigated on the 7 th day of treatment. Pretreatment and 7 th -day RDW levels were 16.2% ± 1.9% and 15.3% ± 2.2%, respectively. The difference was statistically significant (P = 0.002) [ Table 3 ].
No correlation was determined between RDW and age, mean corpuscular volume, Hb, leukocytes, or CRP (data not shown) values. ROC analysis was performed to determine the RDW cutoff point predicting 30-day mortality [ Figure 1 ]. Area under the curve value of 0.736 (95% confidence interval: 0.550-0.922, P < 0.001) was determined. An RDW value >16.5% predicted Table 4 ].
Discussion
Two important conclusions emerge from this study. The first is that RDW can be used in assessing response to treatment in CAP. The second is that elevated RDW is an independent predictor of mortality in CAP.
The relationship between RDW levels and CAP is unclear. Inflammation and oxidative stress can affect red cell homeostasis. RDW has recently been shown to be an independent risk factor in inflammatory and infectious conditions. Ku et al. reported that RDW is an independent predictor of mortality in Gram-negative bacteremia. [8] Elevated RDW levels have also been associated with acute and chronic hepatitis B [9] and inflammatory bowel disease activity. [10] Lippi et al. reported a correlation between high RDW and elevated inflammation indices, including ESR and CRP. This correlation was independent of concomitant diseases and applied even after exclusion of anemic patients from the statistical analysis. [11] CURB-65 and PSI are frequently used in deciding on hospitalization and predicting mortality. However, these risk models are complex and may not be capable to be used everywhere. RDW, however, is part of CBC, which can also be measured at the first stage. In our study, RDW >16.5 was identified as a warning parameter on the subject of patient hospitalization.
When RDW level was compared with CURB-65 and PSI scoring at multivariate analysis, the risk of 30-day mortality was 9-fold higher in patients with elevated RDW. An RDW cutoff point of >16.5% exhibited 78% sensitivity and 70% specificity for 30-day mortality.
In a retrospective study of 744 patients, Lee et al.
reported 5-fold greater 30-day mortality in subjects with RDW >15.2 compared to those with RDW <13.3%. [5] Braun et al. reported 2.5-fold greater 90-day mortality in subjects with RDW levels above 15 as compared to those with RDW levels below that. [12] In the light of these data, RDW appears to be a parameter that can be effectively used in predicting mortality in CAP.
Treatment of pneumonia needs to be started as early as possible. Guidelines emphasize the importance of the timing of antibiotherapy for therapeutic success.that should be started <4 h after CAP diagnosis. [13] Markers, such as CRP and procalcitonin, are used in the diagnosis and follow-up of pneumonia. However, these are generally investigated in secondary and tertiary hospitals and are relatively expensive. RDW is capable of being used in follow-up of treatment of CAP since a significant decrease was observed after treatment in 1 st -and 7 th -day RDW values (P = 0.002). RDW level increase compared to basal level has also been shown in patients with sarcoidosis that progressed during monitoring. [14] RDW is part of CBC, an inexpensive test, which can be easily applied even in primary health institutions. Elevated RDW levels can warn physicians regarding the severity of the disease, and changes in RDW levels can be used in the evaluation of the effectiveness of the treatment being administered.
RDW levels can increase with age. Braun et al. enrolled patients aged <60 and showed that RDW was correlated with mortality and morbidity in hospitalized patients with CAP. [12] In another study involving RDW, the mean age of enrolled patients was 70.1 years. [5] The mean age of our patients was 69 years, and no correlation between RDW and age was determined. In addition, advanced age did not predict mortality at multivariate analysis in our study.
There are several limitations to this study. The first is the relatively low patient number. It was therefore impossible to investigate secondary conditions such as intensive care and vasopressor requirements. Second, we were unable to investigate the causes of RDW elevation, such as iron or Vitamin B12 deficiency, which are capable of obscuring the relationship between RDW and adverse outcomes. However, anemia was not identified as a predictor of all-cause mortality at multivariate regression analysis.
Conclusion
An elevated RDW level at the time of presentation can be used as an independent predictor providing clues about mortality, and pre-and post-treatment investigation of RDW can be used as an important parameter in assessing response to antibiotherapy.
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